Beam Therapeutics (BEAM) Stock
Clinical stage biotech developing precision genetic medicines. Here's the price, business snapshot, and what's worth knowing about Beam Therapeutics in October 2026.
Beam Therapeutics Inc (BEAM) is a clinical-stage biotechnology company developing precision genetic medicines using base editing — a gene-editing approach that alters individual DNA letters without cutting the DNA double helix. With a market capitalisation around $3.02 billion, Beam is primarily research and development-driven: value depends heavily on clinical trial readouts, regulatory reviews and the commercial potential of a still-early pipeline. The company has collaborations and licensing arrangements typical of the sector and relies on capital markets or partners to fund development. Investors should be aware that biotech equities can be volatile and subject to binary outcomes from trial results; revenue is limited while R&D and clinical costs remain high. This makes Beam a higher-risk, potentially higher-reward holding suitable for investors comfortable with long horizons and concentrated biotech exposure. This is educational information, not personalised advice.
Beam Therapeutics (BEAM) Stock Forecast
Analyst price target, next 12 months
$52.89
+115.9% vs today's $24.50
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Beam Therapeutics have a consensus 12-month target of $52.89, above the current price of $24.50.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Beam Therapeutics stock with a target price of $52.89, indicating strong growth potential.
Financial Health
Beam Therapeutics is performing well with strong revenue and cash flow, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Precision gene editing
Beam’s base-editing platform aims for targeted DNA changes that could address genetic diseases, though clinical proof of concept remains essential and uncertain.
Clinical catalysts ahead
Upcoming trial readouts and regulatory updates can materially affect valuation, making timing and binary outcomes important for investors to monitor.
Long-term potential
If successful, therapies may address unmet needs and create durable value, but development is costly and outcomes are not guaranteed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
